The STARRT trial: A cost comparison of optimal vs sub-optimal initiation of dialysis in Canada

Journal of Medical Economics

Volumn 15, Issue 1, 2012, Pages 96-104

  Piwko, Charles ^a   Vicente, Colin ^a   Marra, Lou ^b   Jivraj, Farah ^b   Appel, Eva ^a   Wolpin, Jacob ^a   Camacho, Fernando ^c   Mendelssohn, David C ^d   McFarlane, Phil A ^e  

^a PIVINA Consulting Inc   (Canada)

^b Janssen Inc   (Canada)

^c DAMOS Inc   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Canadian; Cost comparison; Dialysis; STARRT

Indexed keywords

CYANOCOBALAMIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; FOLIC ACID; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; REPLAVITE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTERIOVENOUS FISTULA; ARTICLE; CANADA; CENTRAL VENOUS CATHETER; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; CANADA; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 84856044998     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.630850     Document Type: Article

References (30)

1. Amedia CA, Perazella MA. Transition of patients from chronic kidney disease to end-stage renal disease: better practices for better outcomes. Dis Manag 2006;9:311-5 (Pubitemid 44904292)
2. Curtis BM, Barrett BJ, Djurdjev O, et al. Evaluation and treatment of CKD patients before and at their first nephrologist encounter in Canada. Am J Kidney Dis 2007;50:733-42 (Pubitemid 47588558)
3. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002;40:611-22 (Pubitemid 34971291)
4. Schold JD, Srinivas TR, Kayler LK, et al. The overlapping risk profile between dialysis patients listed and not listed for renal transplantation. Am J Transplant 2008;8:58-68
5. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 2007;7:149-69
6. Mendelssohn DC, Wish JB. Dialysis delivery in Canada and the United States: a view from the trenches. Am J Kidney Dis 2009;54:954-64
7. McFarlane PA. Reducing hemodialysis costs: conventional and quotidian home hemodialysis in Canada. Semin Dialysis 2004;17:118-24 (Pubitemid 38560983)
8. Berar-Yanay N, Leshno M, Hertzeanu L, et al. Cost-effectiveness of angio-tensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel. Harefuah 2008;147:211-5
9. Coustasse A. Hospital costs and clinical characteristics of continuous renal replacement therapy patients: a continuous ethical dilemma. J Hosp Mark Public Relations 2008;18:187-95
10. Dimkovic N, Oreopoulos D. Management of elderly patients with end-stage kidney disease. Semin Nephrol 2009;29:643-9
11. Khan S, Amedia Jr CA, Economic burden of chronic kidney disease. J Eval Clin Pract 2008;14:422-34 (Pubitemid 351643256)
12. Marchant K. Diabetes and chronic kidney disease: a complex combination. Br J Nurs 2008;17:356-61
13. Pereira BJ. Optimization of pre-ESRD care: the key to improved dialysis outcomes Clinical conference. Kidney Int 2000;57:351-65 (Pubitemid 30227791)
14. Mendelssohn DC, Curtis B, Yeates K, et al, for the STARRT Study investigators. Nephrol Dial Transplant 2011;26(9):2959-65
15. Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia, PA: Saunders, 1985
16. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Int Med 1997;127:757-63 (Pubitemid 27446562)
17. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
18. Rosenbaum P, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8
19. D'Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
20. Rosenbaum P, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24
21. Bank of Canada. Inflation Calculator. Available at: http://www. bankofcana-da.ca/en/rates/inflation-calc.html. Accessed May 2011
22. McFarlane PA, Redelmeier DA. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kid Int 2002;66:2216-22 (Pubitemid 35366178)
23. Dranitsaris. The cost of blood transfusions in cancer patients: a reanalysis of a Canadian economic evaluation. J Oncol Pharm Pract 2000;6:37-42
24. Panther Meds. Buy cheap venofer, http://www.panthermeds.com/products/ Venofer/. Accessed May 2011
25. Regie de l'assurance maladie Quebec. Available at: https://www. prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste-Med/Liste-Med/liste-med- mod1-2009-07-08-en.pdf. Accessed May 2011
26. Ontario Ministry of Health and Long Term Care. JOI/ODPD. Ontario Drug Benefit Program e-Formulary May 2011
27. Canadian online pharmacy. Prices for prescription and over the counter medication. http://www.canadapharmacyonline.com/DrugInfo.aspx?name¼ Replavite6365. Accessed May 2011
28. Goeree R. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995;18:455-64 (Pubitemid 26026315)
29. Coyte PC. An economic evaluation of hospital-based hemodialysis and home-based peritoneal dialysis for pediatric patients. Am J Kidney Dis 1996;27:557-65 (Pubitemid 26106604)
30. Canadian Institute for Health Information (CIHI). Treatment of end-stage organ failure in Canada 1999 to 2008. 2010 Annual Report. Available at: http://wwwkidneyca/DocumentDoc?id¼855. Accessed May 2011